A prospective multicenter clinical study on the optimization of the treatment system for allergic bronchopulmonary aspergillosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035421

Enrollment

Unknown

Registered

2020-08-10

Start date

2021-01-01

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic bronchopulmonary aspergillosis

Interventions

Group 1:Glucocorticoid

Group 2:Glucocorticoid + itraconazole

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Subjects must voluntarily participate in the study and comply with the study regulations, understand and comply with the corresponding examination,drug dose and follow-up plan, and voluntarily sign the written informed consent; 2. Aged 18 to 70 years old; 3. Previous history of asthma or pulmonary cystic fibrosis; 4. Elevated serum total IgE (>417 IU/ml or >1000 ug/L); 5. Elevated serum aspergillus specific IgE or IgG, or aspergillus (or other molds) positive allergen tachycardia skin test.

Exclusion criteria

Exclusion criteria: 1. Unable to cooperate with the related inspection of the project or other reasons; 2. Associated with COPD, interstitial pneumonia, active tuberculosis, community-acquired pneumonia, lung cancer, pulmonary heart disease, pulmonary embolism and other pulmonary diseases; 3. A history of alcohol or narcotics abuse, drug use, or a history of mental illness (such as schizophrenia, obsessive-compulsive disorder, depression), antagonistic personality, negative motivation, paranoia or other emotional or intellectual problems that may affect the informed effectiveness of participating in this study; 4. with pregnancy or lactation; 5. The last 2 months of antifungal therapy >=5 days; 6. Liver and kidney function abnormalities: ALT or AST value > 3 times of the normal value;Bilirubin >2mg/dl; Blood creatinine (Scr) or urea nitrogen (BUN) value > 2 times of the normal value; 7. Allergic to antifungal drugs; 8. A history of life-threatening asthma, including intubation and admission to intensive care; 9. participating in other clinical research projects.

Design outcomes

Primary

Measure	Time frame
Annual acute attack rate of asthma;	—

Secondary

Measure	Time frame
ACT score;AQLQ score;pulmonary function;FENO;Blood total IgE;Blood Eosnophils;PEF variation;	—

Countries

China

Contacts

Public ContactMeiling Jin

Zhongshan Hospital, Fudan University

mljin118@163.com+86 13701640522

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026